← Leaderboards
Louis Chesler
University Of California San Francisco
$664,506
Attributed
$728,838
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $161.4K · FY2005–24$200K$150K$100K$50K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$728,838 · 2
By mechanism
K08$600,174 · 1
OT2$128,664 · 1
Top collaborators
- Swen Hoelder1 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- David H Stokoe$2,605,737
- Katherine Kurshan Matthay$7,757,759
- Wolfgang Michael Korn$7,457,664
- Douglas Hanahan$19,892,030
- Bin Liu$11,320,971
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsXenograft ProcedureMycn GeneProgramsResponseTumorMalignant Childhood NeoplasmMutantPathway InteractionsPre-ClinicalResearch PersonnelResistanceSolid NeoplasmTransgenic ModelChildIn VivoCell LineMouse ModelNeuroblastomaOncogenesPharmaceutical PreparationsCellsChildhoodAttention
Grant awards (6)
PROTECT - Develop therapeutics to target oncogenic drivers of solid tumours in children$128,664
OT2 · FY2024 · CA · contact PI
Role of MYCN inhibition in NBL Tumor Progression$54,000
K08 · FY2009 · NS · contact PI
Role of MYCN inhibition in NBL Tumor Progression$61,956
K08 · FY2008 · NS · contact PI
Role of MYCN inhibition in NBL Tumor Progression$161,406
K08 · FY2007 · NS · contact PI
Role of MYCN inhibition in NBL Tumor Progression$161,406
K08 · FY2006 · NS · contact PI
Role of MYCN inhibition in NBL Tumor Progression$161,406
K08 · FY2005 · NS